{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T22:51:42Z","timestamp":1779144702934,"version":"3.51.4"},"reference-count":21,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2010,3,19]],"date-time":"2010-03-19T00:00:00Z","timestamp":1268956800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2010,10]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Atazanavir (ATV) boosted with ritonavir (ATV\/r) is a potent, well\u2010tolerated, once\u2010daily protease inhibitor (PI). Few data are available on this agent as a treatment simplification option for patients taking other PIs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>The aim of the study was to determine the effectiveness and safety of ATV\u2010containing regimens in patients who have simplified their antiretroviral treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>SIMPATAZ was a multicentre, prospective, noninterventional study in patients who had undetectable HIV RNA on their current PI\u2010containing therapy and who were switched to an ATV\/r\u2010based regimen. Patients underwent a routine physical examination, and data were collected on HIV RNA levels, CD4 cell counts, liver function, lipid parameters, adverse reactions, adherence to treatment and patient satisfaction.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 183 patients were enrolled in the study and included in the analysis (80% were male, 29% had AIDS, and 52% were coinfected with HIV and hepatitis B virus or hepatitis C virus). The median baseline CD4 count was 514\u2003cells\/\u03bcL. Median exposure to previous HIV therapy was 8 years, and 32% of patients had a history of PI failures. Lopinavir boosted with ritonavir was the most frequent PI replaced (62%) and tenofovir+lamivudine \/emtricitabine the backbone most used during the study (29%). The study drug was discontinued early by 25 patients (14%), two of whom discontinued as a result of adverse events (Hodgkin lymphoma and vomiting). Two patients died (lung cancer and myocardial infarction). At month 12, 93% of the study population had an undetectable HIV RNA viral load. Hyperbilirubinaemia &gt;3\u2003mg\/dL and increased alanine aminotransferase levels&gt;200 IU\/L were observed in 38.5% and 4.4% of patients, respectively. Median changes from baseline to month 12 in total cholesterol, triglycerides and low\u2010density lipoprotein cholesterol were \u221213\u2003mg\/dL (\u22127%; <jats:italic>P<\/jats:italic>&lt;0.0001), \u221219\u2003mg\/dL (\u221213%; <jats:italic>P<\/jats:italic>&lt;0.0001) and \u22127\u2003mg\/dL (\u22126%; <jats:italic>P<\/jats:italic>=0.021), respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In a real\u2010world setting, switching from other PIs to ATV\/r is a well\u2010tolerated and safe option for improving the lipid profile and for retaining virological response in controlled pretreated patients.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1468-1293.2010.00827.x","type":"journal-article","created":{"date-parts":[[2010,3,21]],"date-time":"2010-03-21T00:09:39Z","timestamp":1269130179000},"page":"545-553","source":"Crossref","is-referenced-by-count":15,"title":["Effect of simplification from protease inhibitors to boosted atazanavir\u2010based regimens in real\u2010life conditions"],"prefix":"10.1111","volume":"11","author":[{"given":"R","family":"Rubio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Carmena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V","family":"Asensi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Echevarr\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Flores","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Ribera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Zarraga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Ocampo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"De La Fuente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MA","family":"Sep\u00falveda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"AI","family":"Mari\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Minguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Vicent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JA","family":"Cart\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Moyano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Esteban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Mahillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Gonz\u00e1lez\u2010Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the GESIDA 44\/04 SIMPATAZ study group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,9,3]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199803263381301"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki119"},{"key":"e_1_2_7_4_2","first-page":"103","article-title":"Atazanavir\/Ritonavir","volume":"44","author":"Von Hentig N.","year":"2008","journal-title":"a review of its use in HIV therapy"},{"key":"e_1_2_7_5_2","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents.Guidelines for the use of antiretroviral agents in HIV\u2010infected adults and adolescents. Department of Health and Human Services. January 29 2008; 1\u2013128. Available athttp:\/\/www.aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf(accessed 2 December 2008)."},{"key":"e_1_2_7_6_2","first-page":"555","article-title":"Antiretroviral treatment of adult HIV infection","volume":"300","author":"Hammer SM","year":"2008","journal-title":"2008 recommendations of the International AIDS Society USA panel"},{"key":"e_1_2_7_7_2","unstructured":"Panel de Expertos de GESIDA y Plan Nacional sobre el SIDA.Recommendations from the GESIDA\/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update January 2008). Available athttp:\/\/www.gesida.seimc.org\/pcientifica\/dcconsensos.asp?apnv0=pcientifica&apnvA=dcconsensosyrc&appag=dcconsensos_txt.htm(accessed 2 December 2008)."},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2007.0136"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2007.00541.x"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl191"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021589"},{"key":"e_1_2_7_12_2","unstructured":"BeckerS RachlisA GillJet al. Successful substitution of protease inhibitors with efavirenz (EFV) in patients with undetectable viral loads \u2013 a prospective randomized multicenter open\u2010label study (DMP 049).Programme and Abstracts of the Eighth Conference on Retroviruses and Opportunistic Infections. Chicago IL 2001 [Abstract 20]."},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1086\/317424"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1086\/324629"},{"key":"e_1_2_7_15_2","first-page":"830","article-title":"Simplification therapy with once\u2010daily emtricitabine, didanosine, and efavirenz in HIV\u20101 infected adults with viral suppression receiving a protease inhibitor\u2010based regimen","volume":"191","author":"Molina JM","year":"2005","journal-title":"a randomized study"},{"key":"e_1_2_7_16_2","unstructured":"Summary of Product Characteristics.Reyataz. Available athttp:\/\/www.emea.europa.eu\/humandocs\/PDFs\/EPAR\/reyataz\/H\u2010494\u2010PI\u2010en.pdf(accessed 2 December 2008)."},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000216371.76689.63"},{"key":"e_1_2_7_18_2","first-page":"646","article-title":"CASTLE Study Team. Once\u2010daily atazanavir\/ritonavir versus twice\u2010daily lopinavir\/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral\u2010naive HIV\u20101\u2010infected patients","volume":"23","author":"Molina JM","year":"2008","journal-title":"48 week efficacy and safety results of the CASTLE study"},{"key":"e_1_2_7_19_2","unstructured":"MallolasJ PodzamczerD DomingoPet al. Efficacy and safety of switching from boosted lopinavir (LPV\/r) to boosted atazanavir (ATV\/r) in patients with virologic suppression receiving a LPV\/r\u2010containing HAART: The ATAZIP study.Abstracts of the 4th IAS Conference on HIV Pathogenesis Treatment and Prevention. Sydney Australia July 2007 [Abstract WEPEB117LB]."},{"key":"e_1_2_7_20_2","unstructured":"MolinaJM Andrade\u2010VillanuevaJ Echevarr\u00edaJet al. Efficacy and safety of boosted once\u2010daily atazanavir and twice\u2010daily lopinavir regimens in treatment\u2010naive HIV\u20101 infected subjects. CASTLE: 48 weeks results.Abstracts of the 15th Conference on Retroviruses and Opportunistic Infections. Boston MA February 2008 [Abstract 37]."},{"key":"e_1_2_7_21_2","unstructured":"MoyleG AndradeJ GirardPMet al. Continuation of BID boosted PI vs switch to once\u2010daily ATV\/RTV for the management of lipodystrophy: 48 weeks primary analysis of the 96 weeks multicenter open\u2010label randomized prospective ReAL Study.Abstracts of the XVII International AIDS Conference. Mexico City August 2008 [Abstract MOPDB103]."},{"key":"e_1_2_7_22_2","first-page":"925","article-title":"Liver toxicity of antiretroviral combinations including atazanavir\/ritonavir in patients co\u2010infected with HIV and hepatitis viruses","volume":"61","author":"Pineda JA","year":"2008","journal-title":"impact of pre-existing liver fibrosis"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1293.2010.00827.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1293.2010.00827.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T21:03:11Z","timestamp":1698699791000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1293.2010.00827.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,3]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["10.1111\/j.1468-1293.2010.00827.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1293.2010.00827.x","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,3]]}}}